According to news reporting originating from Lausanne, Switzerland, by NewsRx correspondents, research stated, "To determine the long-term effect of natalizunnab (NTZ) treatment on the expression of integrins and chenmokine receptors involved in the migration of T cells towards the central nervous system (CNS). We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment."
By a News Reporter-Staff News Editor at Biotech Week Data detailed on Drugs and Therapies have been presented. According to news reporting originating from Lausanne, Switzerland, by NewsRx correspondents, research stated, "To determine the long-term effect of natalizunnab (NTZ) treatment on the expression of integrins and chenmokine receptors involved in the migration of T cells towards the central nervous system (CNS). We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment."
Our news editors obtained a quote from the research from University Hospital, "We assessed the ex-vivo expression of phenotype markers (CCR7 and CD45RA), CNS-addressing integrins (CD11a, CD49d and CD29) and chemokine receptors (CXCR3 and CCR6) in CD4+ or CD8+ T-cell subsets by flow cytometry. As compared to the pre-NTZ values, there was a marked increase in central memory (CCR7+/CD45RA-) CD4+ T cells and in effector memory (CCR7-/CD45RA-) CD8+ T cells at 12 and 24 months. In addition to an expected downregulation of both VLA-4 subunits (CD49d/CD29), we also found decreased T-cell expression of CXCR3 at 12 months, and of CD11a (LFA-1 alpha(L) subunit) at 12 months, but mostly at 24 months of NTZ treatment."
According to the news editors, the research concluded: "Our data show a nadir of CD11a expression at 2 years of NTZ treatment, at the peak of incidence of progressive multifocal leukoencephalopathy (PML), indirectly suggesting that a lack of these molecules may play a role in the onset of PML in NTZ-treated patients."
For more information on this research see: Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 alpha-chain (CD11a) in MS patients. Multiple Sclerosis Journal, 2014;20(7):837-842. Multiple Sclerosis Journal can be contacted at: Sage Publications Ltd, 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England. (Sage Publications - www.sagepub.com/; Multiple Sclerosis Journal - msj.sagepub.com)
The news editors report that additional information may be obtained by contacting S. Jilek, CHU Vaudois, Dept. of Clin Neurosci, CH-1011 Lausanne, Switzerland. Additional authors for this research include A. Mathias, M. Canales, A. Lysandropoulos, G. Pantaleo, M. Schluep and R.A. Du Pasquier (see also Drugs and Therapies).
Story Source: The above story is based on materials provided by PHARMACYCHOICE
Note: Materials may be edited for content and length
